Similar articles

• [Clinical trials on protective efficacy of statins for cardiovascular events due to hyperlipidemia (J-LIT, 4S, CARE, LIPID etc)].

  Higashikata T. Higashikata T. Nihon Rinsho. 2004 Mar;62 Suppl 3:628-36. Nihon Rinsho. 2004. PMID: 15171447 Review. Japanese. No abstract available.
• Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?

  Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A. Comparato C, et al. Nutr Metab Cardiovasc Dis. 2001 Oct;11(5):328-43. Nutr Metab Cardiovasc Dis. 2001. PMID: 11887430 Review.
• Vascular health: the emerging appreciation of the endothelium.

  Talley JD. Talley JD. J Ark Med Soc. 1997 Feb;93(9):454-5. J Ark Med Soc. 1997. PMID: 9046759 No abstract available.
• [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].

  Motz W. Motz W. MMW Fortschr Med. 2003 Oct 9;145(41):48. MMW Fortschr Med. 2003. PMID: 14655487 German. No abstract available.
• Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.

  Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ. Bullano MF, et al. Pharmacotherapy. 2006 Apr;26(4):469-78. doi: 10.1592/phco.26.4.469. Pharmacotherapy. 2006. PMID: 16553504